Inito is pushing beyond fertility tracking as it works to build a broader at-home diagnostics platform powered by AI-designed antibodies. Founded by CEO Aayush Rai and CTO Varun Venkatesan, the company launched in 2021 with the goal of making quantitative hormone testing accessible outside clinical labs. Inito’s fertility monitor allows users to measure estrogen, luteinizing hormone (LH), progesterone metabolite (PdG), and follicle-stimulating hormone (FSH) on a single test strip, with AI models interpreting hormone patterns to identify fertile windows and confirm ovulation. Since launch, the platform has analyzed more than 30 million hormone data points, positioning Inito as a data-rich player in consumer health diagnostics.
The company’s next focus is applying AI to antibody design, a shift it believes could unlock new categories of at-home tests that are currently impractical with conventional methods. Instead of relying on antibodies grown and manually screened in animals, Inito uses AI models to predict protein folding, design synthetic antibodies, and evaluate millions of variants virtually before producing them in the lab. Venkatesan says the approach improves sensitivity, consistency, and stability, enabling detection of biomarkers that have traditionally required lab-based testing.
To support this expansion, Inito has raised $29 million in a Series B round, bringing total funding to approximately $45 million, which the company plans to use to scale manufacturing, expand internationally, and develop tests spanning pregnancy, menopause, and broader hormone and endocrine monitoring.
